Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis
- PMID: 16929488
- DOI: 10.1002/mc.20241
Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis
Abstract
Inappropriate fibroblast growth factor (FGF) signaling is involved in most tissue-specific pathologies including cancer. Previously we showed that inappropriate expression and chronic activity of FGF receptor (FGFR) 1 in hepatocytes accelerated diethylnitrosamine (DEN)-initiated hepatocarcinogenesis. Here we showed that although widely expressed FGF1 and FGF2 are frequently upregulated in hepatocellular carcinoma (HCC), germline deletion of both FGF1 and FGF2 had no effect on DEN-initiated hepatocarcinogenesis. Thus overexpression of FGF1 or FGF2 may be a consequence rather than contributor to hepatoma progression. FGF21 is the first of 22 homologues whose expression has been reported to be preferentially in the liver. We showed that similar to FGF1 and FGF2, FGF21 mRNA was upregulated in neoplastic and regenerating liver after partial hepatectomy (PH) and CCl4 administration. In situ hybridization analysis confirmed that in contrast to FGF1 and FGF2, expression of FGF21 mRNA was limited to hepatocytes. Forced overexpression of FGF21 in hepatocytes by gene targeting had no apparent impact on normal liver development and compensatory response to injury. Surprisingly, overexpression of FGF21 delayed the appearance of DEN-induced liver tumors. At 8 and 10 mo, only 10% and 30% of transgenic mice, respectively, developed adenomas compared to 50% (all adenomas) and 80% (60% adenoma/20% HCC) in the wild-type (WT) mice. However, the incidence and burden of HCC at 10 mo and later was equal in the FGF21 transgenic and WT mice. We propose that FGF21 may delay development of adenomas through activation of resident hepatocyte FGFR4 at early times, but counteracts the delay by acceleration of progression to HCC through interaction with ectopic FGFR1 once it appears in hepatoma cells. This indicates a dual function of FGF21 that may reflect changes in FGFR isotype during progression of differentiated hepatoma cells.
Copyright (c) 2006 Wiley-Liss, Inc.
Similar articles
-
Ectopic activity of fibroblast growth factor receptor 1 in hepatocytes accelerates hepatocarcinogenesis by driving proliferation and vascular endothelial growth factor-induced angiogenesis.Cancer Res. 2006 Feb 1;66(3):1481-90. doi: 10.1158/0008-5472.CAN-05-2412. Cancer Res. 2006. PMID: 16452204
-
Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress.BMC Gastroenterol. 2013 Apr 17;13:67. doi: 10.1186/1471-230X-13-67. BMC Gastroenterol. 2013. PMID: 23590285 Free PMC article.
-
Fibroblast growth factor 2 facilitates the differentiation of transplanted bone marrow cells into hepatocytes.Cell Tissue Res. 2006 Feb;323(2):221-31. doi: 10.1007/s00441-005-0077-0. Epub 2005 Oct 14. Cell Tissue Res. 2006. PMID: 16228231
-
Molecular pathogenesis of hepatocellular carcinoma: altering transforming growth factor-β signaling in hepatocarcinogenesis.Dig Dis. 2011;29(3):284-8. doi: 10.1159/000327560. Epub 2011 Aug 9. Dig Dis. 2011. PMID: 21829019 Review.
-
Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma.Oncology. 2011;81(5-6):372-80. doi: 10.1159/000335472. Epub 2012 Jan 20. Oncology. 2011. PMID: 22269894 Review.
Cited by
-
The FGF metabolic axis.Front Med. 2019 Oct;13(5):511-530. doi: 10.1007/s11684-019-0711-y. Epub 2019 Sep 7. Front Med. 2019. PMID: 31495905 Free PMC article. Review.
-
Effects of short-term continuous subcutaneous insulin infusion on fasting plasma fibroblast growth factor-21 levels in patients with newly diagnosed type 2 diabetes mellitus.PLoS One. 2011;6(10):e26359. doi: 10.1371/journal.pone.0026359. Epub 2011 Oct 26. PLoS One. 2011. PMID: 22046277 Free PMC article.
-
Inventing new medicines: The FGF21 story.Mol Metab. 2013 Dec 27;3(3):221-9. doi: 10.1016/j.molmet.2013.12.003. eCollection 2014 Jun. Mol Metab. 2013. PMID: 24749049 Free PMC article. Review.
-
Characterization of FGFR signaling pathway as therapeutic targets for sarcoma patients.Cancer Biol Med. 2016 Jun;13(2):260-8. doi: 10.20892/j.issn.2095-3941.2015.0102. Cancer Biol Med. 2016. PMID: 27458533 Free PMC article.
-
FGF/FGFR signaling in health and disease.Signal Transduct Target Ther. 2020 Sep 2;5(1):181. doi: 10.1038/s41392-020-00222-7. Signal Transduct Target Ther. 2020. PMID: 32879300 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous